Key points from article :
Dr. Stephanie Planque, a co-founder of Covalent Bioscience, discusses the company's advancements in age-related disease treatments. Covalent Bioscience, founded in 2010, utilises a technology based on catalytic antibodies, or catabodies, to target and clear harmful proteins in diseases like Alzheimer’s and transthyretin amyloidosis.
Their research focuses on developing catabodies, such as Alzyme and Cardizyme, which aim to remove toxic protein aggregates without causing inflammation, a common side effect with conventional treatments.
The technology involves chemically modified analogs of proteins to create catabodies that bind permanently and effectively to targets. These modifications help isolate and generate catabodies or irreversible antibodies (IrAbs) from antibody libraries.
E-vaccines, a novel aspect of their approach, stimulate the immune system to produce these catabodies and IrAbs against specific targets, offering potential advantages over traditional vaccines.
Covalent Bioscience is currently in the preclinical stage, working on bringing these catabody therapies to human trials within the next few years. They are seeking investment and partnerships to advance their research and development. Their lead products, Alzyme and Cardizyme, aim to address unmet medical needs by targeting amyloid proteins associated with aging and disease.
The company has received funding from various sources, including angel investors and non-profit organisations. They require additional funding to complete preclinical milestones and initiate human clinical trials. Covalent Bioscience’s innovative approach holds promise for improving treatments for age-related diseases and potentially extending the effectiveness of vaccines.
